Replies to post #250860 on Biotech Values

[Mufaso]

Viking Therapeutics price target raised to $120 from $38 at Truist 07:31 VKTX

Truist raised the firm's price target on Viking Therapeutics to $120 from $38 and keeps a Buy rating on the shares. The firm is citing "further evidence" of VK2735 being a"best in class" GLP-1 weight loss drug profile. VK2735 appears to be about twice as effective in weight loss compared to tirzepatide and numerically superior to even retatrutide, a triple agonist, all the while exhibiting superior tolerability, the analyst tells investors in a research note.

Read more at:
https://thefly.com/n.php?id=3874637

[DewDiligence]

Maybe a slight fall [Thursday] was in order because of the raise or maybe because the stock had some short covering…

I do not understand how short-covering could cause a stock to decline.